Jounce Therapeutics Inc (JNCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Jounce Therapeutics Inc (JNCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH464036D
  • |
  • Pages: 44
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Jounce Therapeutics Inc (Jounce) is a clinical stage immunotherapy company that develops therapies that enable the immune system to attack tumors. The company provides JTX-2011, an anti-ICOS monoclonal antibody which stimulates T effector cells to enhance anti-tumor activity; JTX-4014, an anti-PD-1 antibody for combination therapy in tumor eradication. It harnesses its proprietary product engine to gain new insights into cancer immunotherapy and explore multiple mechanisms of action against a broad spectrum of targets. Jounce offers services in the areas of tumor immunology, antibody discovery and optimization and integrated translational capabilities. The company has collaborations with the universities, general hospitals and cancer centers. Jounce is headquartered in Cambridge, Massachusetts, the US.

Jounce Therapeutics Inc (JNCE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Jounce Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Jounce Therapeutics Raises USD56 Million in Series B Financing 11

Jounce Therapeutics Raises USD 47 Million In Series A Financing 13

Partnerships 14

OncoSec Medical Enters into Agreement with Jounce Therapeutics 14

Celgene Enters into Agreement with Jounce Therapeutics 15

Jounce Therapeutics Enters Into Research Agreement With Adimab 16

Licensing Agreements 17

Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 17

Jounce Therapeutics Amends Licensing Agreement for JTX-2011 18

Equity Offering 20

Jounce Therapeutics Files Registration Statement to Raise up to USD250 Million in Public Offering of Securities 20

Jounce Therapeutics Files Registration Statement to Raise up to USD280.7 Million in Public Offering of Shares 21

Jounce Therapeutics Raises USD117.12 million in IPO 22

Jounce Therapeutics Raises USD139 Million in Private Placement of Shares 24

Jounce Therapeutics Inc-Key Competitors 25

Jounce Therapeutics Inc-Key Employees 26

Jounce Therapeutics Inc-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 28

Financial Announcements 28

Aug 09, 2018: Jounce Therapeutics reports second quarter 2018 financial results 28

May 09, 2018: Jounce Therapeutics Reports First Quarter 2018 Financial Results 30

Mar 08, 2018: Jounce Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 31

Nov 13, 2017: Jounce Therapeutics Reports Third Quarter 2017 Financial Results 33

Aug 09, 2017: Jounce Therapeutics Reports Second Quarter 2017 Financial Results 34

May 09, 2017: Jounce Therapeutics Reports First Quarter 2017 Financial Results 36

Mar 10, 2017: Jounce Therapeutics reports net income for Q4, provides fiscal 2017 guidance 38

Mar 10, 2017: Jounce Therapeutics reports net income for Q4 39

Corporate Communications 40

Dec 14, 2017: Jounce Therapeutics Added to NASDAQ Biotechnology Index 40

Oct 23, 2017: Jounce Therapeutics Appoints Luis A. Diaz, Jr., M.D., to its Board of Directors 41

Aug 15, 2017: Jounce Therapeutics Names Hugh Cole as Chief Business Officer and Head of Corporate Development 42

Mar 31, 2017: Jounce Therapeutics Added to Russell 2000, 3000 and Microcap Indexes 43

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44

List of Figures

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Jounce Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

List of Tables

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Jounce Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Jounce Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

Jounce Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Jounce Therapeutics Raises USD56 Million in Series B Financing 11

Jounce Therapeutics Raises USD 47 Million In Series A Financing 13

OncoSec Medical Enters into Agreement with Jounce Therapeutics 14

Celgene Enters into Agreement with Jounce Therapeutics 15

Jounce Therapeutics Enters Into Research Agreement With Adimab 16

Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 17

Jounce Therapeutics Amends Licensing Agreement for JTX-2011 18

Jounce Therapeutics Files Registration Statement to Raise up to USD250 Million in Public Offering of Securities 20

Jounce Therapeutics Files Registration Statement to Raise up to USD280.7 Million in Public Offering of Shares 21

Jounce Therapeutics Raises USD117.12 million in IPO 22

Jounce Therapeutics Raises USD139 Million in Private Placement of Shares 24

Jounce Therapeutics Inc, Key Competitors 25

Jounce Therapeutics Inc, Key Employees 26

Jounce Therapeutics Inc, Subsidiaries 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Jounce Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17745
Site License
USD 500 INR 35490
Corporate User License
USD 750 INR 53235

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com